Physiological characteristics of spontaneously developed diabetes in male WBN/Kob rat and prevention of development of diabetes by chronic oral administration of synthetic trypsin inhibitor (FOY-305).
The male WBN/Kob rats spontaneously develop diabetes mellitus with age. In this study, we examined how glucose tolerance, potency of insulin release, and histology of the pancreas were changed with age in this model. Furthermore, we examined the effect of FOY-305, a synthetic trypsin inhibitor, on this model. Male WBN/Kob rats were divided into two groups: one group fed on standard pellet diet (STD group) and the other on pellet containing 0.1% FOY-305 (FOY group) for 56 weeks after age 4 weeks. Oral glucose (2 g/kg) tolerance test, histology of the pancreas, and glucose (8.3 mM)- and arginine (10 mM)-stimulated insulin release from the isolated perfused pancreas were examined at 8, 20, 40, and 60 weeks of age in both groups. Pancreatic insulin content was examined at 60 weeks. In the STD group, impairment of glucose tolerance and destruction and fibrosis of pancreatic tissues progressed with age. Glucose-stimulated insulin release was remarkably reduced with age, while arginine-stimulated insulin release was preserved. By contrast, in the FOY group, development of glucose intolerance was delayed and the pancreas showed fewer pathologic changes compared with the STD group. Insulin releases in response to both glucose and arginine were preserved at all ages examined. Total pancreatic insulin content at 60 weeks of age was significantly greater than that of the STD group. The male WBN/Kob rat is a new type of diabetic model that shows a similar pattern of insulin release to that in rat with non-insulin-dependent diabetes mellitus and also shows unique histopathological changes in exocrine pancreas. FOY-305 was effective in preventing the development of diabetes in this model, although its mechanism is still unknown.
Shimoda
I
I
Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Koizumi
M
M
Shimosegawa
T
T
Shishido
T
T
Ono
T
T
Sato
K
K
Ishizuka
J
J
Toyota
T
T
D000284:Administration, Oral; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D005951:Glucose Tolerance Test; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000473:pathology; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
D004952:Esters; D006146:Guanidines; D007328:Insulin; D014361:Trypsin Inhibitors; C034532:camostat; D016670:Gabexate